PurposeSpectral-domain optical coherence tomographies (OCTs) from different companies do not give identical retinal thicknesses. The purpose of this study was to evaluate if differences in thickness when using a spectral domain Cirrus OCT or a Heidelberg Spectralis are due to hardware differences, or if they are caused by the segmentation algorithms.MethodsThirty-seven healthy eyes were examined within the same session with a Cirrus OCT and a Spectralis OCT, the latter using averaged B-scans. Scans from similar positions and passing the fovea were analyzed by custom-made software. Thickness was analyzed at the fovea, the central 1-mm line and the 6-mm line.ResultsWhen Cirrus and Spectralis scans were analyzed with the same software, the retinal thickness at the foveal center was 225.92 μm (SD 17.0) using the Cirrus and 228.70 μm (SD 18.4) using the Spectralis; the difference of 2.78 μm was not significant (p = 0.055). For the central 1 mm, the difference was 1.78 μm (p = 0.0414), and for all points out to 6 mm, the Spectralis retinal thickness was also significantly larger than the Cirrus thickness (p = 0.0052), though the mean difference was only 1.85 μm. Also for the RPE_OScomplex, Spectralis measured a greater thickness than did Cirrus, with a mean of 3.32 μm (p < 0.0001) for all points.ConclusionThe retinal thicknesses from the Cirrus and from the Spectralis differed by 14 μm with the standard software of the instruments, and by less than 3 μm when analyzed with the same custom-made software, indicating that the major differences between the two SD-OCT systems are due to differences in their built-in software algorithms.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.